Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 105
3 140
2 36
1 21
Curative setting
A 41
C 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 34
Central Nervous System Malignancies 1
Endocrine Tumours 20
Gastrointestinal Cancers 59
Genitourinary Cancers 54
Gynaecological Malignancies 32
Head and neck cancer 9
Melanoma 21
RET fusion-positive tumours 1
Refractory NTRK fusion–positive cancers 2
Sarcoma 9
Skin Cancers 6
TMB-H solid tumours 1
Thoracic Malignancies 70
dMMR/MSI-H solid tumours 1
Curative setting
Brain Tumours 0
Breast Cancer 7
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 0
Melanoma 11
RET fusion-positive tumours 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 1
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.
Quality of Life Checklist To evaluate ESMO-MCBS score adjustments based on quality of life

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Talimogene Laherparepvec -  Subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF) EMA: Indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. FDA: Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Melanoma Cutaneous Melanoma - OPTiM
    3

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Avelumab - Single arm (Phase II) Adult patients with metastatic Merkel cell carcinoma (MCC) Skin Cancers Merkel cell carcinoma - JAVELIN Merkel 200 (Part B - treatment-naïve patients)
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Trastuzumab - Chemotherapy Patients with HER2-positive early breast cancer following surgery, ChT (neoadjuvant or adjuvant) and RT (if applicable) Breast Cancer Early Breast Cancer HER2+ HERA
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel (Randomised phase II study) Neo-adjuvant HER2 overexpressed invasive ductal breast Breast Cancer Early Breast Cancer HER2+ NeoSphere
    C

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Trastuzumab emtansine (T-DM1) - Lapatinib + capecitabine As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy Breast Cancer Breast Cancer HER2+ EMILIA
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo HER2-positive locally recurrent unresectable or metastatic breast cancer with no prior anti-HER2 therapy or ChT for metastatic disease Breast Cancer Breast Cancer HER2+ CLEOPATRA
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Lapatinib Trastuzumab Lapatinib HER2-positive, hormone receptor-negative metastatic breast cancer after progression on prior trastuzumab + ChT regimen(s) Breast Cancer Breast Cancer HER2+ HR- EGF104900
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Palbociclib Fulvestrant Fulvestrant + placebo Hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy Breast Cancer Breast Cancer HR+ HER2- PALOMA-3
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Palbociclib Letrozole Letrozole + placebo First-line postmenopausal, ER-positive, HER2-negative locally advanced metastatic breast cancer Breast Cancer Breast Cancer HR+ HER2- PALOMA-2
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Palbociclib Letrozole Letrozole (Randomised phase II study) 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- PALOMA-1/TRIO-18
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.